Important Factors for Sponsors to Consider When Outsourcing...
Pharma Tech Outlook

Important Factors for Sponsors to Consider When Outsourcing Clinical Trials

Pharma Tech Outlook | Friday, April 28, 2023

Outsourcing provides a flexible option for sponsors, allowing them to fully or partially outsource different elements of trials.

FREMONT, CA: Due to the increasing competition in the global clinical research market, small to mid-size pharmaceutical and biotech companies often resort to outsourcing clinical trials to specialist clinical research organisations (CROs) and functional service providers (FSPs) for their expertise, services, and facilities. Collaborating with external experts helps smaller companies tackle significant operational hurdles and achieve successful study delivery, levelling the playing field with larger, well-resourced competitors.

Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.

Why are clinical trials Outsourced?

The competition in the pharmaceutical and biotech industries has grown significantly in recent years, with greater incentives for being the first to market or discovering the next breakthrough drug. Moreover, advances in medical technology have made clinical studies more intricate and extensive.

The heightened competition in the industry has resulted in a greater need for cost-effective clinical trials, and the increased complexity of studies has amplified the demand for specialised expertise in therapeutic and trial management areas. As an example, sponsors can outsource clinical trial management to a contract research organisation (CRO) to control study costs. A full-service CRO partner can leverage their extensive in-house experience across various clinical trials and address the specific challenges of the study more effectively. They can also offer superior site management and risk mitigation capabilities, resulting in potential cost and timeline efficiencies.

Types of Clinical Trial Outsourcing

Contract research organisations (CROs) offer different outsourcing models to cater to the needs of each study. Some studies may only require certain key capabilities, while others may require complete outsourcing services. Regardless, these outsourcing models can enhance operational efficiencies and promote growth for sponsor companies, leading to more cost-effective and timely drug development.

1. Functional Service Provider (FSP)

Functional service providers (FSPs) specialise in offering a singular or a limited number of clinical functions to support a study, such as clinical data management or central laboratory services. The CRO provides the required personnel and facilities to perform specific tasks on a contractual basis, with the staff following the sponsor's procedures. This model is beneficial for smaller biotech and pharmaceutical companies, as it allows access to specialised services on a case-by-case basis and eliminates the need for in-house recruitment of personnel for these specific roles.

2. Full-Service Outsourcing (FSO)

Full-service outsourcing (FSO) refers to outsourcing all or most of the clinical development tasks to a CRO. This means that the CRO handles the entire trial management and delivery process, which is beneficial for sponsors who lack the capacity, facilities, or expertise to carry out the project themselves. Entrusting the entire project to a single provider can also reduce the management workload of the sponsor organisation.

3. Hybrid Model

Hybrid models in clinical trial outsourcing combine aspects of both full-service outsourcing (FSO) and functional service provider (FSP) models. This approach is particularly useful for more complex trials, as it can be tailored to meet the specific needs of each trial component and can adapt as required. For instance, a clinical trial might use a combination of FSO and FSP outsourcing models based on location and logistics, or it might use a mixture of FSO and FSP models across different study phases.

Considerations for Successful Collaboration

To ensure a successful clinical trial, it is crucial to maintain a positive collaboration between sponsors and the clinical research organisation. The following tips can help establish and maintain a good working relationship:

• Establish Clear Expectations Early on: At the beginning of the partnership between a sponsor and a clinical research organisation for a clinical trial, it is crucial to set up clear and precise expectations to ensure that both parties are aligned. This involves defining the roles and responsibilities of each party, establishing timelines, and outlining communication channels.

• Understand Each Other’s Language: Building a strong working relationship between sponsors and CROs requires trust and mutual understanding. This can be achieved by gaining knowledge of each other's language, culture, and processes. Organising introductory sessions can be a useful tool to help internal and external teams develop a positive working relationship.

• Implement a Communication Plan: To ensure a successful clinical trial collaboration between sponsors and CROs, maintaining open and regular communication is crucial. It is important to establish clear communication expectations and develop a centralised communication plan that utilises cloud-based data sharing and secure messaging platforms. Both parties should communicate not only about issues that need to be addressed but also about the progress made and challenges encountered during the study.

• Develop Risk Assessment Plans: In clinical research, it is crucial to conduct risk assessments. Sponsors and CROs should collaborate closely to develop strategies and procedures for risk reduction. This should be a continuous process, with on-site risk assessments being carried out to ensure proper data quality management and risk mitigation throughout the study.

Outsourcing has become increasingly important in clinical research in recent years, as competition in conducting clinical trials has intensified. Contract research organisations have become more essential due to the need for operational efficiency and therapeutic expertise. Outsourcing provides a flexible option for sponsors, allowing them to fully or partially outsource different elements of the trial.

More in News

 The landscape of pharmaceutical discovery has been transformed by the rise and ongoing advancement of high-throughput screening (HTS) and automation technologies. The ability to rapidly and efficiently test large libraries of chemical compounds against biological targets has become essential in the search for new therapies. Today, HTS, powered by automation, is central to early-stage drug discovery, accelerating the identification of promising lead compounds and laying the groundwork for future breakthrough treatments. The synergy between HTS and automation is fundamental to the efficiency and success of modern drug discovery processes. Automation integrates a diverse range of robotic systems and software solutions to manage the repetitive and labor-intensive tasks inherent in HTS, enhancing both accuracy and throughput while minimizing human error. One key area is compound management, where automated systems leverage robotic arms and advanced software to store, retrieve, and prepare compound libraries with precision. These technologies facilitate the accurate aliquoting of compounds into microplate formats, ensuring consistency across assays. In liquid handling, automation plays a critical role through the use of sophisticated pipetting systems that dispense precise volumes of liquids—ranging from assay reagents to cells and test compounds—into microplates. These systems, with their unwavering precision, can vary from basic multi-channel pipettes to complex robotic platforms capable of managing nanoliter volumes with high accuracy. Similarly, the execution of assays is streamlined through automated incubation, mixing, and detection processes. Robotic arms transfer microplates between instruments such as incubators—calibrated to maintain specific environmental conditions—and various readers that detect assay endpoints, including fluorescence, luminescence, and absorbance. Recent Advancements and Trends in HTS and Automation HTS and automation is constantly evolving to improve efficiency, data quality, and tackle complex biological questions. Recent trends include miniaturization and microfluidics, label-free detection technologies, integration with AI and Machine Learning, High-Content Screening (HCS), automation of complex biological models, increased focus on data quality and reproducibility, and cloud computing and data management. Miniaturization and microfluidics enable precise control over fluid flow and mixing, enabling complex cellular assays and studying biological processes. Label-free detection methods, such as surface plasmon resonance and bio-layer interferometry, provide physiologically relevant data for protein-protein interactions and drug binding kinetics. AI and ML are transforming HTS by enabling intelligent compound library design, predictive modeling, automated image analysis, and sophisticated data mining. Impact on Pharmaceutical Innovation HTS and automation have significantly accelerated drug discovery by reducing time, increasing the probability of finding active compounds, and reducing costs. HTS can screen diverse compound libraries, identify novel drug targets and mechanisms of action, and improve lead compound quality. The initial investment in HTS infrastructure, while significant, can lead to long-term cost savings, providing a reassuring financial benefit. It also facilitates the identification of compounds with desirable properties. HTS and automation, the bedrock of modern pharmaceutical innovation, hold immense potential. Their capacity to swiftly and effectively screen extensive chemical spaces against biological targets has significantly hastened the identification of lead compounds. The ongoing progress in miniaturization, label-free detection, AI integration, and the automation of complex biological models is poised to further amplify the potency and influence of HTS. This progression fuels the excitement for the discovery of groundbreaking medicines to meet unmet medical needs. The future of pharmaceutical discovery is intricately tied to the continuous evolution and application of these potent technologies, promising a future. ...Read more
Automation and artificial intelligence have greatly expanded their reach, driving the pharmaceutical regulatory affairs sector to gear up for integrating cutting-edge technologies with human expertise. The development of artificial intelligence (AI) in the life sciences sector is significantly transforming the pharmaceutical industry. Current initiatives aim to enhance and accelerate regulatory affairs by incorporating automated processes and leveraging technologies such as generative AI, machine learning (ML), natural language processing (NLP), and large language models (LLMs). Given these technological advancements, what implications does this altered landscape hold for regulatory teams and their operational processes? Essentially, the focus has transitioned towards utilizing automation to enhance the capabilities of regulatory professionals, resulting in the development of what is referred to as 'the augmented regulatory worker.' What Does Augmentation Look Like? Pharmaceutical companies need to assess the characteristics of the automated tasks involved to determine the ideal degree of enhancement necessary to improve human skills and productivity. For instance, repetitive and low-complexity tasks are ideally suited for complete automation through the use of bots, rule-based algorithms, or integrated operational systems. Conversely, as the complexity of tasks escalates—such as in data extraction, transformation, pattern recognition, and content creation—technologies like AI, ML, NLP, and LLM provide significant advantages in streamlining operations. These semi-automated processes still necessitate expert validation and final approval by a regulatory professional. Generative AI The past year has prominently featured Generative AI, making it essential to examine the potential impact of this technology on enhancing regulatory workforce capabilities. Despite being in its nascent phase, the anticipated benefits are considerable. Generative AI can significantly enhance the regulatory field by streamlining data mining, analytics, software operations, and content generation. By improving these processes, AI has the potential to alleviate the workload on professionals while increasing the efficiency and accuracy of strategic risk evaluations, predictive analyses of regulatory results, and interactions with health authorities. Integrated Solutions It is essential to prioritize integrated platforms that can enhance and unify processes derived from diverse internal and external regulatory intelligence sources. In addition to the collection of regulatory intelligence, an improved methodology positively impacts the publishing workflow within regulatory affairs. Such solutions, along with their sophisticated automation features, can notably increase the efficiency of manual bookmarking and hyperlinking tasks involved in this process. ...Read more
Commercial pharmaceutical teams can spend weeks preparing an analysis only to find that prescribing patterns or market access conditions have changed before the recommendations reach the field. A segmentation exercise commissioned against an earlier data extract may be technically sound but poorly timed. Executives evaluating agentic data science platforms must establish whether faster answers preserve analytical consistency and remain grounded in approved enterprise data. Speed alone offers little protection against an incorrect calculation reaching a brand team. Repeated preparation of structured data consumes substantial analyst time. Patient records and physician activity may sit in different datasets, each requiring defined relationships before a commercial question can be answered. A platform should preserve those definitions between analyses rather than reconstruct them for every request. Otherwise, two teams examining the same treatment pathway may produce different results because they applied different filters. Buyers should examine how business rules are encoded and how the system establishes which records are eligible for a particular analysis. Traceable calculations matter more than fluent explanations. Generative AI introduces a specific division of responsibility. Natural language interfaces make complex analysis accessible to commercial managers, but language models are not dependable numerical engines by themselves. Agentic platforms should separate interpretation of a request from execution of statistical calculations, using controlled methods for the latter. The system must also handle longer workflows that require successive analytical steps rather than treating every request as an isolated query. Results should be reproducible when the same data and assumptions are supplied, with sufficient detail for data scientists to review the method. “Orcana.AI's semantic layer maintains enterprise data definitions and business rules across analyses, keeping the same assumptions available to different teams.” Pharmaceutical data access comes with restrictions that ordinary business intelligence implementations may not encounter. Patient-level records require appropriate privacy controls, while commercial functions may have different permissions to view measures or underlying datasets. An automated agent working across several analytical steps must retain those restrictions throughout the process. Executives should establish whether permissions and approved channel definitions are enforced by the architecture itself or depend on users phrasing prompts correctly. The latter creates unnecessary room for inconsistent handling of sensitive information. Commercial usefulness depends on the time between finding a pattern and changing an action. Campaign measurement may identify underperforming promotional channels, while a market access analysis can reveal barriers affecting a particular patient population. Neither finding improves execution automatically. Buyers should examine how outputs reach existing field systems and whether recommended changes remain subject to appropriate review. Reusable workflows should also accommodate updated data, permitting teams to revisit earlier decisions without commissioning a complete analysis each time. Orcana.AI   provides a pharma-focused agentic data science platform that combines generative AI for interpreting requests with a deterministic Python engine for calculations. Orcana.AI's semantic layer maintains enterprise data definitions and business rules across analyses, keeping the same assumptions available to different teams. Its specialized agents support segmentation, marketing mix assessment and campaign measurement, alongside treatment-pathway analysis. Orcana.AI uses governed workflows and access restrictions to control what agents can analyze and disclose. Its analytics bench addresses recurring questions, while deeper agents handle extended analytical work that would otherwise require separate projects. Pharmaceutical commercial analytics teams managing repeated cross-brand studies, particularly those needing reproducible calculations within established data permissions, are the intended users of this approach. ...Read more
Pharmacovigilance is a broad term encompassing the collection, monitoring, evaluation, and prevention of adverse effects from medications and treatments. It is a process-driven, scientific discipline within the pharmaceutical industry. The primary goals of pharmacovigilance include establishing signal detection systems and utilizing advanced data analytics to proactively oversee the introduction of new drugs in large patient populations, ultimately promoting safer drug use. Complex international rules, growing data quantities, numerous data sources, broader risk monitoring, and precise patient event recording worldwide are all factors increasing pressure on pharmacovigilance systems to change. Appropriate analytics are essential, but businesses often spend more on data processing than creative research and new technology, leading to less-than-ideal results. Implementing artificial intelligence and embracing emerging technologies throughout the pharmaceutical value chain can have numerous advantages. Here are some ways AI can Help enhance pharmacovigilance: An Expedited Path to the Market Drug development requires a lot of time because pharmaceutical companies benefit from competitive product-to-market lead times, which increase market share and profitability. Solutions utilizing artificial intelligence can facilitate quicker decision-making. Without sacrificing patient safety, a shorter end-to-end drug development cycle translates into a faster route to market. Cost-Effective Processes Pharmaceutical firms have historically used outsourcing or labor offshoring to meet the ever-increasing resource demands and expenses. That's one method of cost reduction. Another option is to invest in custom software solutions for automation and augmentation, which can result in noticeable cost savings and a significant return on investment. The business can lower the price of a product recall or an update to the label.  More accuracy and efficiency in PV services reduce the entire cost of the drug development process. The most significant financial impact on a pharmacovigilance budget is caused by case processing. The most important chance to reduce the expenses associated with the pharmaceutical development process may be to automate the reporting and management of safety cases using machine learning algorithms. Expedited Error-Free Reporting Using artificial intelligence technologies to automate repetitive jobs is a great idea. Human mistakes can be eliminated by automating the time-consuming and expensive direct annotation of source documents, provided that stringent guidelines are followed. The initial centralized medication safety monitoring stage is NLP, which automates safety reporting. Data-Driven Insights for Safety Due to growing data sets and sources, processing pharmacovigilance data solely using expert labor is not feasible. There is an enormous need for simplification, and data science solutions may help by offering predictions, intelligent, valuable insights, and automated analysis. Regulatory Compliance Over the past few years, pharmacovigilance activities have become increasingly expensive for pharmaceutical corporations due to the advent of stricter regulations worldwide. Businesses must continue to adhere to the ever-changing laws in many nations. A digitalized, adaptable architecture supporting the drug development process and global drug monitoring is the solution to being robust. ...Read more

Weekly Brief